The Hemp Cliff: What Public Law 119-37 Means for Florida Cannabis Defense Before November 12, 2026
- May 27
- 11 min read
Section 781 rewrites federal hemp law. Florida has not adopted the federal 0.4-milligram container cap. For Florida cannabis defense, the immediate issue is not slogans about "legal hemp" or "illegal marijuana." It is proof: the product, the packaging, the statute, and the lab method.
• • •
On November 12, 2026, Section 781 of Public Law 119-37 is scheduled to narrow the federal definition of hemp. The federal reset replaces the old delta-9-only federal threshold with a "total tetrahydrocannabinols" framework, excludes cannabinoids synthesized or manufactured outside the plant, and removes from "hemp" any final hemp-derived cannabinoid product containing more than 0.4 milligrams combined total per retail container of total THC and other HHS-determined THC-like cannabinoids.
Florida law is different. Florida § 581.217 defines hemp by total delta-9-tetrahydrocannabinol concentration, and Florida Rule 5K-4.034 defines that term as Δ9-THC + (0.877 × Δ9-THCA) for hemp and hemp extract intended for human consumption. Florida has not adopted Public Law 119-37's federal 0.4 mg per-container cap or its broader "total tetrahydrocannabinols plus similar-effect cannabinoids" framework.
That mismatch matters. After November 12, 2026, a product may fail the federal hemp definition while still requiring a separate Florida-law analysis in a Florida criminal prosecution. The State still has to prove the charged Florida controlled-substance offense under Chapter 893. For defense lawyers, the work remains concrete: demand the full lab file, preserve provenance and packaging, examine whether the test actually answers the statutory threshold, and do not let a qualitative "cannabis" identification substitute for quantitative proof.
What changes federally on November 12, 2026
Public Law 119-37 was approved on November 12, 2025. Section 781 amends 7 U.S.C. § 1639o, the federal hemp-definition statute, and the amendment is effective 365 days after enactment. That makes the operative date November 12, 2026, absent later congressional action, agency action, or litigation affecting implementation.
The 2018 Farm Bill defined hemp as Cannabis sativa L. and its derivatives with no more than 0.3% delta-9 THC on a dry-weight basis. That delta-9-only wording created the legal space for much of the hemp-derived cannabinoid market: CBD products, delta-8 products, delta-10 products, hemp delta-9 edibles and beverages, THCA flower, and other products that were marketed as hemp because they did not exceed the delta-9 threshold.
Section 781 narrows that space in three important ways.
First, the new federal definition uses total tetrahydrocannabinols concentration, including THCA, rather than the old delta-9-only formulation. The statute itself does not spell out a particular mathematical formula, but it plainly moves federal law away from a delta-9-only threshold. CRS summarizes the change as covering compounds such as delta-8 THC, delta-10 THC, and THCO.
Second, Section 781 excludes certain hemp-derived cannabinoid products if they contain cannabinoids that are not capable of being naturally produced by Cannabis sativa L., or cannabinoids that are capable of being naturally produced but were synthesized or manufactured outside the plant. That language is aimed at the commercial reality that many hemp-market intoxicants are produced by chemical conversion rather than direct extraction in naturally occurring amounts.
Third, and most dramatically for consumer products, the statute excludes any final hemp-derived cannabinoid product containing more than 0.4 milligrams combined total per container of total tetrahydrocannabinols, including THCA, plus other cannabinoids that have similar effects or are marketed as having similar effects as determined by the Secretary of Health and Human Services.
That is not 0.4 milligrams per serving. It is 0.4 milligrams per container. The statute defines "container" as the innermost wrapping, packaging, or vessel in direct contact with the final hemp-derived cannabinoid product for retail sale, such as a jar, bottle, bag, box, packet, can, carton, or cartridge. Bulk shipping containers and nonessential outer wrappings are excluded.
A 30-count jar of 10-milligram hemp delta-9 gummies would contain 300 milligrams of THC in the retail container, 750 times the federal cap. Even a jar containing only 3 total milligrams across all gummies would exceed the federal cap by 7.5 times.
Industry estimates should be identified as advocacy estimates, not legal findings. The U.S. Hemp Roundtable has estimated that approximately 95% of hemp extract products currently on the market would be swept outside the federal hemp definition if Congress does not intervene.
What Florida law actually says
Florida's state hemp program is codified at § 581.217, Florida Statutes. The statute says hemp-derived cannabinoids are not controlled substances or adulterants if they comply with that section.
The key definition is not identical to the old federal definition. Florida defines hemp as Cannabis sativa L. and its derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers that have a total delta-9-tetrahydrocannabinol concentration not exceeding 0.3% on a dry-weight basis, except that hemp extract may not exceed 0.3% total delta-9 THC on a wet-weight basis.
Florida Rule 5K-4.034 then defines "total delta-9 tetrahydrocannabinol concentration" as Δ9-THC + (0.877 × Δ9-THCA).
That means the current Florida defense analysis is not accurately described as "delta-9 only." Florida already accounts for THCA in the total delta-9 calculation for hemp and hemp extract intended for human consumption. But Florida has not adopted the new federal 0.4 mg per-container limit, and Florida has not adopted the new federal "total tetrahydrocannabinols plus HHS-listed similar-effect cannabinoids" standard.
As of this review, Florida's 2026 SB 1270, the food and hemp products bill that would have amended § 581.217, died in the Senate Agriculture Committee on March 13, 2026.
Why the mismatch matters in Florida criminal cases
Florida's controlled-substance chapter defines "cannabis" broadly, but it expressly excludes hemp as defined in § 581.217.
That matters because a Florida cannabis prosecution is governed by Florida criminal statutes. A product's loss of federal hemp status after November 12, 2026 does not automatically prove that the product is "cannabis" under Florida law. The State still has to prove the Florida offense charged.
At the same time, state-law hemp compliance is not a federal shield. Florida § 581.217 states that the section does not authorize a licensee to violate federal or state law. A Florida retailer or consumer may therefore face a real federal-law problem even where the Florida criminal-law analysis is different.
The cleanest way to describe the post-November 12 landscape is this: a product may be outside federal hemp and therefore subject to federal CSA control, while still requiring a separate Florida-law proof analysis before it can support a Florida cannabis conviction.
Federal law also has its own preemption rule. The Controlled Substances Act expressly says Congress did not intend to occupy the entire field of controlled-substance law unless there is a positive conflict such that state and federal law cannot consistently stand together. CRS likewise notes that federal and state cannabis laws generally operate independently, with both potentially applying where no positive conflict exists.
Do not overstate "Schedule I"
Many summaries say products falling outside hemp become "Schedule I marijuana." For ordinary non-medical retail hemp products, that may often be the practical federal-risk shorthand. But the more precise legal phrasing is that the product falls outside the federal hemp exception and becomes subject to CSA control as marijuana or THC unless another exception or scheduling rule applies.
The CSA definition of marijuana excludes hemp as defined in 7 U.S.C. § 1639o, and the federal schedule for tetrahydrocannabinols excludes tetrahydrocannabinols in hemp. But 2026 federal rescheduling language complicates any blanket statement because DEA's April 2026 final rule placed certain FDA-approved marijuana drug products and state medical-marijuana-license activity in Schedule III. That rule does not make ordinary hemp-store intoxicants federally lawful, but it is a reason to write "CSA-controlled" rather than using "Schedule I" as a universal label.
The lab problem after hemp legalization
The strongest Florida defense issue is not simply "GC-MS bad." The better issue is whether the State's test answers the legal question.
A qualitative lab result saying a sample is "cannabis" does not, by itself, prove that the substance is illegal cannabis rather than hemp. Florida appellate law now recognizes the problem. In Campbell v. State, the Second DCA held that after hemp legalization, legal hemp and illegal cannabis are indistinguishable by appearance, texture, and odor; chemical testing to determine THC content is needed to avoid misidentification. The court reversed a cannabis-trafficking conviction because the State tested only one bundle and could not use appearance and odor to extrapolate illegal cannabis across the untested bundles.
That holding is especially important in trafficking or multi-package cases. If the State needs a threshold weight, and only some packages were chemically tested, Campbell should be in every defense lawyer's research file.
The scientific issue is method-specific. Gas chromatography-mass spectrometry can be used in cannabis analysis, but it has limitations that matter when the legal issue is a threshold measurement rather than mere identification. NIST has described the difficulties in GC-MS total-THC measurement as well documented, including method-bias issues involving THCA and Δ9-THC behavior in the GC-MS system. NIJ's forensic guidance explains that HPLC can measure Δ9-THC and Δ9-THCA independently, while GC-based methods may rely on injection-port conversion of THCA to THC; NIJ notes that conversion is incomplete, approximately 70% in the described context, and quantitative testing requires additional validated preparation to ensure the sample is homogeneous, dry where required, and appropriate for the instrument.
That creates several defense questions. Was the test qualitative, semi-quantitative, or quantitative? Was the method validated for the actual matrix: flower, vape liquid, gummy, beverage, oil, chocolate, or topical? Did the lab calculate total delta-9 under Florida's formula? Did it use dry weight or wet weight correctly? Did it report uncertainty? Did it separate delta-8, delta-9, delta-10, exo-THC, THCO, and other isomers or derivatives where relevant? Did it homogenize the product before sampling? Did it test each package when the State relies on aggregate weight?
Those are not academic questions. They are the difference between a report that identifies a plant genus and a report that proves a statutory controlled substance.
What changes for pending cases now
For cases pending before November 12, 2026, Public Law 119-37 does not rewrite Florida's criminal statutes. The State must still prove the charged offense under Chapter 893, and hemp remains excluded from Florida's definition of cannabis if it meets § 581.217.
Raw plant material. Cases involving loose flower should focus on the Florida hemp exclusion, the current Florida total-delta-9 standard, and the actual lab method. Defense counsel should demand the lab report, chromatograms, SOPs, validation materials, calibration data, uncertainty calculations, moisture/dry-weight calculations, sample-preparation notes, and chain-of-custody documents.
If the case involves multiple bags, bundles, jars, or packages, Campbell is central. The State should not be allowed to test one portion and infer the rest is illegal cannabis merely because everything looks and smells the same.
Retail hemp products. Cases involving gummies, vapes, beverages, oils, or THCA flower sold as hemp require a product-specific analysis. Preserve the receipt, QR code, certificate of analysis, batch number, label, packaging, expiration date, and any retailer or distributor documentation. Florida law requires hemp extract sold in the state to have a certificate of analysis stating that the tested batch did not exceed 0.3% total delta-9 THC.
The defense issue is not whether the product was marketed as hemp. The issue is whether the State can prove beyond a reasonable doubt that the product was not hemp under Florida law at the relevant time.
Post-November 12, 2026 mismatch cases. After the federal reset, Florida cases may involve products that are federally outside hemp but arguably still within Florida's hemp definition. Those cases will likely produce litigation over statutory interpretation, jury instructions, admissibility of federal-law evidence, and whether the State is trying to use federal status as a substitute for Florida proof.
The defense position should be clear: federal status may be relevant to federal enforcement, but a Florida criminal conviction under Chapter 893 must be proved under Florida law.
The FDA lists matter, but they are not a safe harbor
Section 781 directed FDA, in consultation with other federal agencies, to publish within 90 days lists of cannabinoids known to be capable of natural production by Cannabis sativa L., naturally occurring THC-class cannabinoids, and cannabinoids with similar effects to or marketed as having similar effects as THC-class cannabinoids. FDA was also directed to publish additional specificity about "container."
The 90-day deadline fell on February 10, 2026. Marijuana Moment reported that FDA missed that deadline.
When FDA or HHS finally publishes the lists, defense lawyers and industry participants should read them immediately. But absence from a list should not be treated as a guaranteed safe harbor. Section 781 itself separately excludes non-natural cannabinoids and naturally producible cannabinoids that were synthesized or manufactured outside the plant. The lists will matter most for the category of "similar effects" or "marketed to have similar effects" cannabinoids that count toward the federal cap.
The "container" issue is litigable, not settled
The statute's 0.4 mg limit applies per "container," and "container" means the innermost retail wrapping, package, or vessel in direct contact with the final product.
That will create predictable disputes. A manufacturer may argue that an individually wrapped gummy in its own sealed retail packet is a separate container. An enforcement agency may argue that the outer retail box, bag, or jar is the relevant container. FDA was specifically directed to provide additional container specificity, which means even Congress recognized that the statutory term needs implementation detail.
For defense lawyers, the practical instruction is simple: preserve the packaging exactly as purchased. Do not throw away the jar, pouch, box, foil wrapper, label, QR code, or receipt. In a post-November 12 case, the packaging may become part of the legal definition.
Practical defense checklist
A Florida cannabis defense file should now include:
The seizure date and charging statute.
The exact product form: flower, vape, gummy, beverage, oil, concentrate, or mixed matrix.
The original packaging, label, QR code, batch number, and certificate of analysis.
The complete lab file, not just the summary report.
The lab method: qualitative, semi-quantitative, or quantitative.
The instrument used: GC-MS, GC-FID, HPLC, LC-MS/MS, or another method.
The calculation used for total delta-9 THC.
The dry-weight or wet-weight basis and how it was determined.
The lab's uncertainty, limit of detection, limit of quantitation, calibration, and validation data.
The sampling plan, including whether all relevant packages were tested.
The motion posture: discovery/motion to compel, Daubert or § 90.702 challenge, motion in limine, jury-instruction issue, and judgment-of-acquittal argument. Do not mislabel a lab-reliability issue as a suppression issue unless there is also a constitutional search-and-seizure problem.
What clients are facing
Florida hemp retailers. Florida compliance remains separate from federal risk. Inventory that complies with Florida's current total-delta-9 standard may still fail the federal definition after November 12, 2026. Defense focus: audit inventory, preserve COAs, track supplier representations, and plan for federal-law compliance.
Industry workers. State-licensed conduct is not automatically protected from federal enforcement. Defense focus: understand that Florida licensure is not a federal defense.
Consumers with pending Florida cases. Public Law 119-37 does not change Florida's current proof requirements for pre-effective-date cases. Defense focus: demand lab proof and preserve provenance evidence.
Consumers arrested after November 12, 2026. Products may be federally outside hemp but still require Florida-law analysis in a Florida prosecution. Defense focus: preserve packaging, receipts, COAs, and the exact product configuration.
Medical marijuana patients. Florida medical marijuana operates under a separate statutory scheme. Defense focus: do not conflate medical marijuana authorization, state hemp compliance, and federal hemp status.
Closing
Public Law 119-37 is a major federal hemp reset. It may remove much of the current hemp-derived cannabinoid market from the federal hemp definition after November 12, 2026. But for Florida criminal defense, the statute does not erase the State's burden of proof.
The defense framework is more precise than "hemp is legal" or "the lab says cannabis." The right questions are: Which law applies? What was the product? What was the package? What did the lab actually measure? Was the method validated for the statutory threshold? Did the State prove the substance was Florida cannabis rather than Florida hemp?
For Florida cannabis defendants, the cliff is federal. The courtroom battle remains proof.
• • •
Josef Mitkevicius is the managing attorney of Mitkevicius Law, PLLC, a criminal defense firm serving Florida's First Judicial Circuit. The firm handles cannabis defense matters involving hemp, THC testing, lab methodology, and Chapter 893 prosecutions.
If you or a client are facing cannabis charges in Escambia County or Florida's First Judicial Circuit, Mitkevicius Law, PLLC is available to review the lab work, product provenance, and legal issues in the case. Contact the firm at (850) 558-2527.
Nothing in this article is legal advice. It is general legal information based on federal and Florida law as of May 27, 2026. Statutes, rules, agency guidance, and appellate decisions may change. A person facing a specific charge should consult counsel about the facts of that case.
